Baricitinib
- Generic Name
- Baricitinib
- Brand Names
- Olumiant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N7O2S
- CAS Number
- 1187594-09-7
- Unique Ingredient Identifier
- ISP4442I3Y
- Background
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...
- Indication
In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...
- Associated Conditions
- Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
A Moderate to Severe Rheumatoid Arthritis Study
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 527
- Registration Number
- NCT01721044
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradford, West Yorkshire, United Kingdom
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 588
- Registration Number
- NCT01711359
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Shields, Tyneside, United Kingdom
A Study in Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1307
- Registration Number
- NCT01710358
- Locations
- 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸The Seattle Arthritis Clinic, Seattle, Washington, United States
🇺🇸Valley Arthritis Care, LLC, Phoenix, Arizona, United States
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT01683409
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio Piedras, Puerto Rico
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 271
- Registration Number
- NCT01490632
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carolina, Puerto Rico
Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 145
- Registration Number
- NCT01469013
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toyama, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.